Effect of device design on the in vitro performance and comparability for capsule-based dry powder inhalers

AAPS Journal

Volumn 14, Issue 4, 2012, Pages 667-676

  Shur, Jagdeep ^a   Lee, Sau ^b   Adams, Wallace ^b   Lionberger, Robert ^b   Tibbatts, James ^a   Price, Robert ^a  

^a University of Bath   (United Kingdom)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Computational fluid dynamics; Device design; Dry powder inhaler; In vitro comparability; In vitro performance

Indexed keywords

TIOTROPIUM BROMIDE;

AEROSOL; ARTICLE; CAPSULE BASED DRY POWDER INHALER; COMPARATIVE STUDY; COMPUTATIONAL FLUID DYNAMICS; CONTROLLED STUDY; DRUG CAPSULE; DRUG FORMULATION; FLOW RATE; IN VITRO STUDY; LASER DIFFRACTION; PARTICLE SIZE; POWDER INHALER;

ADMINISTRATION, INHALATION; AEROSOLS; CAPSULES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; EQUIPMENT DESIGN; HYDRODYNAMICS; PARTICLE SIZE; SCOPOLAMINE DERIVATIVES;

EID: 84869139244     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9379-9     Document Type: Article

References (30)

1. Oversteegen L, Rovini H, Belsey MJ. Respiratory drug market dynamics. Nat Rev Drug Discov. 2007;6:695-6.
2. Daley-Yates PT, Parkins DA. Establishing bioequivalence for inhaled drugs; weighing the evidence. Expert Opin Drug Deliv. 2011;8:1297-308.
3. Lee SL, AdamsWP, Li BV, Conner DP, Chowdhury BA, Yu LX. In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases. AAPS J. 2009;11:414-23.
4. Chodosh S, Flanders JS, Kesten S, Serby CW, Hochrainer D, Witek Jr TJ. Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med. 2001;14:309-15.
5. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005;50:1209-27.
6. Newman S, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med. 2002;96:293-304.
7. Byron PR, Hindle M, Lange CF, Longest PW, McRobbie D, Oldham MJ, et al. In vivo-in vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols. J Aerosol Med Pulm Drug Deliv. 2010;23 Suppl 2:59-69.
8. Xu Z, Mansour HM, Mulder T, McLean R, Langridge J, Hickey AJ. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 2. Ipratropium bromide monohydrate and fluticasone propionate. J Pharm Sci. 2010;99:3415-29.
9. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro testing. J Aerosol Med. 1993;6:99-110.
10. Coates MS, Chan H-K, Fletcher DF, Raper JA. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: Air inlet size. J Pharm Sci. 2006;95:1382-92.
11. Coates MS, Fletcher DF, Chan H-K, Raper JA. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: grid structure and mouthpiece length. J Pharm Sci. 2004;93:2863-76.
12. CoatesMS,ChanH-K, FletcherDF,Raper JA. Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses. Pharm Res. 2005;22:1445-53.
13. Coates MS, Fletcher DF, Chan H-K, Raper JA. The role of capsule on the performance of a dry powder inhaler using computational and experimental analyses. Pharm Res. 2005;22:923-32.
14. Inthavong K, Choi L-T, Tu J, Ding S, Thien F. Micron particle deposition in a tracheobronchial airway model under different breathing conditions. Med Eng Phys. 2010;32:1198-212.
15. Wong W, Fletcher DF, Traini D, Chan H-K, Crapper J, Young PM. Particle aerosolisation and break-up in dry powder inhalers 1: evaluation and modelling of venturi effects for agglomerated systems. Pharm Res. 2010;27:1367-76.
16. Wong W, Fletcher DF, Traini D, Chan H-K, Crapper J, Young PM. Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of impaction effects for agglomerated systems. J Pharm Sci. 2011;100:2744-54.
17. Donovan MJ, Kim SH, Raman V, Smyth HD. Dry powder inhaler device influence on carrier particle performance. J Pharm Sci. 2012;101:1097-107.
18. Longest PW, Holbrook LT. In silico models of aerosol delivery to the respiratory tract-development and applications. Adv Drug Deliv Rev. 2012;64:296-311.
19. Longest PW, Hindle M. Condensational growth of combination drug-excipient submicrometer particles for targeted high efficiency pulmonary delivery: comparison of CFD predictions with experimental results. Pharm Res. 2012;29:707-21.
20. Longest PW, Tian G, Walenga RL, Hindle M. Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways. Pharm Res. 2012 (in press).
21. Criée CP, Meyer T, Petro W, Sommerer K, Zeising P. In vitro comparison of two delivery devices for administering formoterol: Foradil P and formoterol ratiopharm single-dose capsule inhaler. J Aerosol Sci. 2006;19:466-72.
22. Shih T-H, Liou WW, Shabbir A, Yang Z, Zhu J. A new kappaepsilon eddy viscosity model for high Reynolds-number turbulent flows. Comput Fluids. 1995;24:227-38.
23. Launder BE, Rodi W. The turbulent wall jet measurements and modeling. Annu Rev Fluid Mech. 1983;15:429-59.
24. ANSYS. ANSYS Fluent 6.3 Users Guide. Lebanon, NH, USA. 2006. At: http://hpce.iitm.ac.in/website/Manuals/Fluent-6.3/Fluent.Inc/fluent6.3/help/ index.htm. Accessed 4 Nov 2010.
25. Zhang Y, Finlay WH, Matida EA. Particle deposition measurements and numerical simulation in a highly idealized mouththroat. J Aerosol Sci. 2004;35:789-803.
26. Liu Y, Matida EA, Gu J, Johnson MR. Numerical simulation of aerosol deposition in a 3-D human nasal cavity using RANS, RANS/EIM, and LES. J Aerosol Sci. 2007;38:683-700.
27. Morsi SA, Alexander AJ. An investigation of particle trajectories in two-phase flow systems. J Fluid Mech. 1972;55:193-208.
28. US Pharmacopeia. <601> Aerosols. Metered-dose inhalers and dry powder inhalers: particle size. Rockville: US Pharmacopeia 35/National Formulary 30, United States Pharmacopeial Convention; 2012.
29. Wachtel H, Ertunc O, Koksoy C, Delgado A. Aerodynamic optimization of Handihaler and Respimat: the roles of computational fluid dynamics and flow visualization. In: Dalby R, Byron P, Peart J, Suman J, Farr S, Young P, editors. Respiratory drug delivery 2008. Illinois: Davis Healthcare International Publishing; 2008. p. 165-74.
30. Nichols S, Wynn E. New approaches to optimizing dispersion in dry powder inhalers-dispersion force mapping and adhesion measurements. In: Dalby R, Byron P, Peart J, Suman J, Farr S, editors. Respiratory drug delivery 2008. Illinois: Davis Healthcare International Publishing; 2008. p. 175-84.